Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy
C. Seguin-Devaux, B. Brandus, J.-M. Plesseria, G. Iserentant, J.-Y. Servais, G. Kanli, I. Behrmann, J. Zimmer, J. H. COHEN, X. Dervillez
This study develops and tests CoMiX immunotherapeutics that activate complement to kill HER2-positive breast cancer cells, showing significant tumor growth inhibition in xenograft models.
bioRxiv · Feb 2, 2024 · PreprintImmunology